A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee
Crossref DOI link: https://doi.org/10.1007/s40264-014-0240-1
Published Online: 2014-11-15
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pacurariu, Alexandra C.
Coloma, Preciosa M.
van Haren, Anja
Genov, Georgy
Sturkenboom, Miriam C. J. M.
Straus, Sabine M. J. M.
Text and Data Mining valid from 2014-11-15